Back to top

Analyst Blog

Merrimack Pharmaceuticals, Inc. (MACK - Snapshot Report) has a license and collaboration agreement with Sanofi (SNY - Analyst Report) for the development of its oncology candidate, MM-121.

Merrimack announced results from two phase II studies evaluating MM-121 for the treatment of women with ER/PR+, HER2 negative breast cancer earlier in the week.

In the first randomized, double-blind, placebo-controlled study, MM-121 was evaluated in combination with Aromasin in women suffering from metastatic breast cancer who had failed prior endocrine therapy. The study failed to meet the primary endpoint. However, the estimated hazard ratio (HR) for progression free survival (PFS) in the overall study population trended in favor of the MM-121 arm. Overall survival data (yet immature) is also in favor of the MM-121 arm.

The other phase II study was conducted in ER/PR+ breast cancer patients in the neoadjuvant setting in combination with Taxol. This study, which did not have a formal specified quantitative endpoint, compared the pathologic complete response (pCR) rate in patients treated with MM-121 in combination with Taxol followed by Doxil and Cytoxan (10.8%), with the pCR rate of patients receiving Taxol alone followed by Doxil and Cytoxan (3.3%).

To strengthen its oncology portfolio, Merrimack entered into an agreement with Actavis (ACT - Analyst Report). As per the agreement, Merrimack will use its proprietary nanoliposomal technology platform to develop and manufacture various pharmaceutical products while Actavis will market the offerings.

Merrimack is eligible to receive payments up to $15.5 million under the deal, including an upfront payment of $2 million and the remaining as near-term development, regulatory and commercial milestone payments related to the first product to come out of the collaboration. For any product emanating from this collaboration, Merrimack will gain a double-digit share of profits on its future global sales.

Merrimack carries a Zacks Rank #3 (Hold). Actelion Ltd. (ALIOF) is a better-ranked stock carrying a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
BANCO DO BR… BDORY 16.78 +8.05%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%